Bang For Buck Binocular

LYMPHOMA NON - HODGKIN: THE NEXT STEPS rituximab
News from the Congress of the American Society of Hematology

VERONA - encouraging results in the treatment of non - Hodgkin lymphoma are the Congress of the American Society of Hematology in Orlando. Rituximab is proving to be potentially curable in 50-60% of cases, a percentage much higher than ten years ago. The spread is true for life expectancy today conceivable around ten - fifteen years. The data is shown in Verona in the 4th Educational meeting sponsored by Roche. Regarding the effectiveness of treatment with traditional chemotherapy, has found a higher success rate approximately 20-30%. Prof. Umberto Vitolo, department of oncology and hematology 2 Azienda Ospedaliera Universitaria of Turin and President of the Italian Lymphoma Foundation, the molecule has represented and still represents a revolution in the specific area of \u200b\u200bcare. The future is then screened in search of new molecules, able to minimize the impact, improve treatments, and healing responses through a more effective defense by antibodies.
What's lymphoma - cancer of the lymph glands, defensive structures to external agents and diseases. It is not a single disease but a group with different characteristics and clinical history., New cases in Italy are about twelve thousand a year. Six out of seven are non - Hodgkin's lymphoma, the other type of lymphoma. Overall, is the most common of all cancers of the blood and fifth among all cancers (at the top, lung, breast and colon - rectum). Hodgkin
Type - shows enlarged cervical lymph nodes, chest, groin. Sometimes, high fever, night sweats, weight loss and itching. Virtually non-existent prevention. Is diagnosed with a levy and an examination of lymphoid tissue and in turn if necessary, CT scans, MRI, lymphography. Type
non - Hodgkin - striking even outside of the lymph glands (stomach, intestine, skin e sistema nervoso). A rischio chi sia in una condizione di carenza difensive anticorpali. Il fumo è una condizione a rischio così come la ipertensione. Si evidenzia con l’ingrossamento delle ghiandole linfatiche, ma in assenza l’identificazione è più complessa, coinvolgendo milza,fegato,midollo osseo. Anche qui, prevenzione non facile da identificarsi. La diagnosi è l’esame istologico del prelievo tissutale,dove possibile. Poi, accertamenti d’immagine se necessari.
Cure – In entrambi i casi ci si basa sulla polichemioteraopia basati sulla combinazione di più farmaci. Dove utile, la seconda fase impiega il trapianto di midollo osseo. Radioterapia nei casi localizzati. Infine, ci sono gli anticorpi monoclonal, biotech drugs created in the laboratory and directed against the protein produced by the tumor.

GIAN UGO BERTI
(reproduction prohibited)